Schwartzberg, L., Kim, E. S., Liu, D. & Schrag, D. Precision oncology: who, how, what, when, and when not? Am. Soc. Clin. Oncol. Educ. Book. 37, 160–169 (2017).

Article  PubMed  Google Scholar 

Flaherty, K. T. et al. The Molecular Analysis for Therapy Choice (NCI-MATCH) trial: lessons for genomic trial design. J. Natl Cancer Inst. 112, 1021–1029 (2020). This paper outlines a landmark precision oncology trial.

Article  PubMed  PubMed Central  Google Scholar 

Letai, A., Bhola, P. & Welm, A. L. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell 40, 26–35 (2022).

Article  PubMed  Google Scholar 

Letai, A. Functional precision cancer medicine—moving beyond pure genomics. Nat. Med. 23, 1028–1035 (2017).

Article  PubMed  Google Scholar 

van Renterghem, A. W. J., van de Haar, J. & Voest, E. E. Functional precision oncology using patient-derived assays: bridging genotype and phenotype. Nat. Rev. Clin. Oncol. 20, 305–317 (2023).

Article  PubMed  Google Scholar 

Bose, S. et al. A path to translation: how 3D patient tumor avatars enable next generation precision oncology. Cancer Cell 40, 1448–1453 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Woo, X. Y. et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat. Genet. 53, 86–99 (2021). This paper demonstrates genomic fidelity between patient tumours and PDXs for a range of cancer types.

Article  PubMed  PubMed Central  Google Scholar 

Liu, Y. et al. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct. Target. Ther. 8, 160 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Sun, H. et al. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nat. Commun. 12, 5086 (2021). This paper investigates genomic and pharmacogenomic relationships between human tumours and pan-cancer PDX models.

Article  PubMed  PubMed Central  Google Scholar 

Byrne, A. T. et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer 17, 254–268 (2017).

Article  PubMed  Google Scholar 

Zanella, E. R., Grassi, E. & Trusolino, L. Towards precision oncology with patient-derived xenografts. Nat. Rev. Clin. Oncol. 19, 719–732 (2022).

Article  PubMed  Google Scholar 

Lynch, I. T. et al. Cancer “avatars”: patient-derived xenograft growth correlation with postoperative recurrence and survival in pancreaticobiliary cancer. J. Am. Coll. Surg. 237, 483–500 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Castillo-Ecija, H. et al. Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas. J. Pathol. Clin. Res. 7, 338–349 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Chen, Q. et al. Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer. Pancreatology 20, 485–492 (2020).

Article  PubMed  Google Scholar 

Vaklavas, C. et al. TOWARDS study: PDX engraftment predicts poor survival in newly diagnosed triple negative breast cancer patients. JCO Precis. Oncon. 8, e2300724 (2024). This paper demonstrates in a prospective clinical trial that PDX models can be used to assess recurrence risk.

Article  Google Scholar 

Hidalgo, M. et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 10, 1311–1316 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Astone, M., Dankert, E. N., Alam, S. K. & Hoeppner, L. H. Fishing for cures: the alLURE of using zebrafish to develop precision oncology therapies. npj Precis. Oncol. 1, 39 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Moy, R. H. et al. Defining and targeting esophagogastric cancer genomic subsets with patient-derived xenografts. JCO Precis. Oncol. 6, e2100242 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Guan, Z. et al. Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis. Mol. Med. Rep. 16, 4784–4790 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Nicolle, R. et al. Pancreatic adenocarcinoma therapeutic targets revealed by tumor–stroma cross-talk analyses in patient-derived xenografts. Cell Rep. 21, 2458–2470 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Conage-Pough, J. E. et al. WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models. Neurooncol. Adv. 5, vdad066 (2023).

PubMed  PubMed Central  Google Scholar 

Pandya, P. H. et al. Integrative multi-OMICs identifies therapeutic response biomarkers and confirms fidelity of clinically annotated, serially passaged patient-derived xenografts established from primary and metastatic pediatric and AYA solid tumors. Cancers (Basel) 15, 259 (2022).

Article  PubMed  Google Scholar 

Hemming, M. L. et al. Preclinical modeling of leiomyosarcoma identifies susceptibility to transcriptional CDK inhibitors through antagonism of E2F-driven oncogenic gene expression. Clin. Cancer Res. 28, 2397–2408 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Hsu, C. L. et al. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor palbociclib as a novel candidate drug for nasopharyngeal carcinoma. J. Exp. Clin. Cancer Res. 37, 233 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Karamboulas, C. et al. Patient-derived xenografts for prognostication and personalized treatment for head and neck squamous cell carcinoma. Cell Rep. 25, 1318–1331.e4 (2018).

Article  PubMed  Google Scholar 

Punzi, S. et al. Development of personalized therapeutic strategies by targeting actionable vulnerabilities in metastatic and chemotherapy-resistant breast cancer PDXs. Cells 8, 605 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Kohale, I. N. et al. Identification of Src family kinases as potential therapeutic targets for chemotherapy-resistant triple negative breast cancer. Cancers (Basel) 14, 4220 (2022).

Article  PubMed  Google Scholar 

Saridogan, T. et al. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Sci. Rep. 13, 20223 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Kim, M. et al. Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood–brain barrier. Mol. Cancer Ther. 17, 1893–1901 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Fiore, D. et al. A novel JAK1 mutant breast implant-associated anaplastic large cell lymphoma patient-derived xenograft fostering pre-clinical discoveries. Cancers (Basel) 12, 1603 (2020).

Article  PubMed  Google Scholar 

De Coninck, S. et al. Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma. Haematologica 109, 1373–1384 (2024).

PubMed  Google Scholar 

Paolino, J. et al. Integration of genomic sequencing drives therapeutic targeting of PDGFRA in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. Clin. Cancer Res. 29, 4613–4626 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Rivera, M. et al. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine. Neoplasia 23, 21–35 (2021).

Article  PubMed  Google Scholar 

Krausert, S. et al. Predictive modeling of resistance to SMO inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma. Neurooncol. Adv. 4, vdac026 (2022).

PubMed